Sanofi-GSK COVID vaccine strongly protects adults in trials

Sanofi and GlaxoSmithKline’s potential COVID-19 vaccine provokes a strong immune response in all adult age groups in preliminary trials, increasing the likelihood of participating in this year’s pandemic battle.

After two doses of the vaccine candidate, participants showed neutralizing antibodies consistent with those found in people who recovered from the disease, according to the results of a phase II trial published Monday. The pharmaceutical company said it plans to begin late-stage testing and production in the coming weeks and hopes to obtain regulatory approval for the vaccine by the end of 2021.

Regulators around the world are already Approved numerous COVID-19 vaccines, Pfizer-BioNTech, Moderna, AstraZeneca, Johnson & Johnson, etc. But experts say more is needed as public health officials compete to vaccinate people in a pandemic that has already killed more than 3.3 million people and is causing economic turmoil. say.

The Sanofi-GSK vaccine was an important part of the European Union’s vaccination strategy and was endorsed by the government of French President Emmanuel Macron.But in the early tests Inadequate immune response in the elderly..

Candidate Sanofi-GSK is participating in approximately 12 vaccines currently in late-stage trials. The two companies plan to administer up to 1 billion doses annually and have contracts to supply to the United States, Canada and developing countries.Public health experts say You will need some vaccine To end the pandemic due to the challenge of rapidly producing and distributing sufficient doses to vaccinate billions of people.

Thomas Triomphe, head of the vaccine division at Sanofi, said:

The results released on Monday came from a phase II trial of 722 volunteers aged 18-95 recruited in the United States and Honduras.

The two companies said the late-stage trials would be attended by approximately 37,000 participants from countries around the world.

Sanofi-GSK COVID vaccine strongly protects adults in trials Source link Sanofi-GSK COVID vaccine strongly protects adults in trials

Related Articles

Back to top button